Assessment
elotuzumab
Relapsed and refractory multiple myeloma in adult patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have shown progression on the last therapy
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations